Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies

INTRODUCTION: In the Cladribine Tablets Treating Multiple Sclerosis Orally (CLARITY) study, cladribine tablets significantly reduced relapse rates and improved findings on magnetic resonance imaging versus placebo in patients with relapsing multiple sclerosis. In the CLARITY Extension study, treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Giovannoni, Gavin, Comi, Giancarlo, Rammohan, Kottil, Rieckmann, Peter, Dangond, Fernando, Keller, Birgit, Jack, Dominic, Vermersch, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8408069/
https://www.ncbi.nlm.nih.gov/pubmed/34370275
http://dx.doi.org/10.1007/s12325-021-01865-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8408069/
https://www.ncbi.nlm.nih.gov/pubmed/34370275
http://dx.doi.org/10.1007/s12325-021-01865-w

Ejemplares similares